Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: AIDS-related Kaposi's sarcoma Condition: after failure of prior systemic chemotherapy or intolerance to such therapy |
Dose: Intravenous – 20 mg/m² Frequency: every 3 weeks Note: As Doxorubicin liposomal |
|
Indication: Ovarian Cancer Condition: disease has progressed or recurred after platinum-based chemotherapy |
Dose: Intravenous – 50 mg/m² Frequency: every 4 weeks Duration: 4 courses minimum Note: As Doxorubicin liposomal |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Tablet – Safety and efficacy not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Dose adjustment not necessary |
Administration
- For IV use only
- Must be given slowly
Side Effect
- Anemia (More than 50%)
- Thrombocytopenia (More than 50%)
- Neutropenia (10-50%)
- Anemia (18.2%)
- Nausea (17%)
- Hand-foot syndrome (50%)
- Nausea (46%)
- Stomatitis (41%)
- Asthenia (40.2%)
- Vomiting (32.6%)
- Rash (28%)
- Constipation (More than 25%)
- Abdominal pain (More than 25%)
- Fever (21.3%)
- Anorexia (20%)
- Diarrhea (20%)
- Peripheral edema
- Dyspepsia
- Pharyngitis
- Dyspnea
- Alopecia
- Asthenia (9.9%)
- Fever (9.1%)
- Diarrhea (7.8%)
- Vomiting (7.8%)
- Stomatitis (6.8%)
- Rash (1-5%)
- Alopecia (1-5%)
- Increased alkaline phosphatase
- Hand-foot syndrome (3.4%)
- Hypotension
- Tachycardia
- Dyspnea
- Hemolysis
- Rash
- Neutropenia (13.3%)
- Anemia (0.4-5.4%)
- Thrombocytopenia (1.3%)
- Abscess
- Acute myeloid leukemia
- Cardiomegaly
- Cardiomyopathy
- Erythema nodosum
- Hyperkalemia
- Hyperuricemia
- Ketosis
- Bone marrow suppression
- cardiotoxicity
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Antibiotics (aminoglycosides), steroids, aminophylline, propranolol
|
Interactions noted, but effects not specified
|
|
Mercaptopurine
|
Potentially Fatal: Cholestasis may be potentiated
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Cardiac Disease
|
Risk of heart failure
|
|
Prior Mediastinal Irradiation
|
Risk of cardiac toxicity
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Powder for injection: Store at 15-30°C.
Solution for injection & liposomal formulations: Refrigerate at 2-8°C. Do not freeze.
Solution for injection & liposomal formulations: Refrigerate at 2-8°C. Do not freeze.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.